Basel/Switzerland and Bridgewater NJ/USA, 10 December 2007 Speedel Holding Ltd (SWX: SPPN) today announced that it has started a Phase IIa clinical trial with its next generation renin inhibitor SPP635 in a more difficult to treat group of patients who suffer from both diabetes and mild-to-moderate hypertension. The new trial will be carried out in Europe with results due in the second half of 2008.
